Combining immunotherapy with chemoradiation for lung-spread nasopharyngeal cancer
Part of Cancer, Ear, nose & throat, Lungs & breathing clinical trials.
This study tests whether adding an immunotherapy drug (PD-1 inhibitor) to standard chemotherapy and radiation can help people whose nasopharyngeal cancer has spread to the lungs or chest area. The treatment aims to shrink tumors and may improve outcomes for patients in this situation.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- You must be able to care for yourself (score of 60 or higher on the Karnofsky scale).
- You must have a confirmed diagnosis of nasopharyngeal squamous cell carcinoma.
- Your cancer must have spread to the lungs, lymph nodes in the chest, or the lining of the lungs, at least 6 months after finishing initial treatment.
- Your kidney, liver, and bone marrow function must be adequate.
- You must not have had prior treatment with an immunotherapy drug (PD-1/PD-L1 inhibitor).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of chemotherapy (three drugs: docetaxel, cisplatin, and fluorouracil) plus an immunotherapy drug (a PD-1 inhibitor, which helps your immune system fight cancer) given before the standard radiation treatment for nasopharyngeal cancer. The goal is to see if this upfront treatment can improve outcomes in patients whose cancer has not spread to distant parts of the body.
This trial tests a new combination of an immunotherapy drug (tislelizumab) plus standard chemoradiotherapy for people with advanced nasopharyngeal carcinoma. It aims to find out if this combination is more effective than standard care alone.
This study tests a new way to treat nasopharyngeal cancer that has spread, using a special type of radiation plus an immunotherapy drug. It is for people who cannot or choose not to have chemotherapy, and it aims to control the cancer while keeping side effects manageable.
This trial tests a combination of a new immunotherapy (QL1706) plus standard chemoradiation for people with advanced nasopharyngeal cancer that hasn't spread to distant organs. The goal is to see if adding this drug helps control the cancer better than standard treatment alone.
This trial tests a new combination of immunotherapy (JS001) and chemotherapy (PFLL) versus a standard regimen (GP) for people with nasopharyngeal cancer that has spread. The goal is to see if the new combination works better at controlling the disease.
This trial tests a new immunotherapy drug (serplulimab) given together with standard chemotherapy and radiation for nasopharyngeal cancer that has spread to nearby lymph nodes. It aims to see if adding this drug can help shrink tumors and improve outcomes.
Hear when a new Lung Metastatic Nasopharyngeal Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.